These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 22245688)

  • 1. Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model.
    Petersen AL; Binderup T; Jølck RI; Rasmussen P; Henriksen JR; Pfeifer AK; Kjær A; Andresen TL
    J Control Release; 2012 Jun; 160(2):254-63. PubMed ID: 22245688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
    Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
    J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of (64)Cu-labeled DOTA-D-Phe(1)-Tyr (3)-octreotide ((64)Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors.
    Hanaoka H; Tominaga H; Yamada K; Paudyal P; Iida Y; Watanabe S; Paudyal B; Higuchi T; Oriuchi N; Endo K
    Ann Nucl Med; 2009 Aug; 23(6):559-67. PubMed ID: 19504168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
    Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
    J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator.
    Sprague JE; Peng Y; Sun X; Weisman GR; Wong EH; Achilefu S; Anderson CJ
    Clin Cancer Res; 2004 Dec; 10(24):8674-82. PubMed ID: 15623652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vivo Evaluation of ¹⁸F-SiFAlin-Modified TATE: A Potential Challenge for ⁶⁸Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET.
    Niedermoser S; Chin J; Wängler C; Kostikov A; Bernard-Gauthier V; Vogler N; Soucy JP; McEwan AJ; Schirrmacher R; Wängler B
    J Nucl Med; 2015 Jul; 56(7):1100-5. PubMed ID: 25977461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
    J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy.
    Lewis JS; Lewis MR; Srinivasan A; Schmidt MA; Wang J; Anderson CJ
    J Med Chem; 1999 Apr; 42(8):1341-7. PubMed ID: 10212119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiosynthesis and Preclinical Evaluation of
    Maschauer S; Heilmann M; Wängler C; Schirrmacher R; Prante O
    Bioconjug Chem; 2016 Nov; 27(11):2707-2714. PubMed ID: 27715017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, Synthesis, and Biological Evaluation of
    Liu F; Liu T; Xu X; Guo X; Li N; Xiong C; Li C; Zhu H; Yang Z
    Mol Pharm; 2018 Feb; 15(2):619-628. PubMed ID: 29278911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy.
    Li WP; Lewis JS; Kim J; Bugaj JE; Johnson MA; Erion JL; Anderson CJ
    Bioconjug Chem; 2002; 13(4):721-8. PubMed ID: 12121126
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Liu F; Zhu H; Yu J; Han X; Xie Q; Liu T; Xia C; Li N; Yang Z
    Tumour Biol; 2017 Jun; 39(6):1010428317705519. PubMed ID: 28618966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo evaluation of PEGylated ⁶⁴Cu-liposomes with theranostic and radiotherapeutic potential using micro PET/CT.
    Petersen AL; Henriksen JR; Binderup T; Elema DR; Rasmussen PH; Hag AM; Kjær A; Andresen TL
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):941-952. PubMed ID: 26646780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative dosimetry of copper-64 and yttrium-90-labeled somatostatin analogs in a tumor-bearing rat model.
    Lewis JS; Laforest R; Lewis MR; Anderson CJ
    Cancer Biother Radiopharm; 2000 Dec; 15(6):593-604. PubMed ID: 11190491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
    Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B
    Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary PET/CT Imaging with Somatostatin Analogs [
    Satpati D; Shinto A; Kamaleshwaran KK; Sarma HD; Dash A
    Mol Imaging Biol; 2017 Dec; 19(6):878-884. PubMed ID: 28349291
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Gao F; Zhang Y; Chen M; Song Z; Dong R; Qiu S; Shen C; Huang X; Geng H; Cheng W; Hu J
    Eur J Pharm Sci; 2024 Feb; 193():106671. PubMed ID: 38104907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodistribution and first clinical results of
    Ilhan H; Lindner S; Todica A; Cyran CC; Tiling R; Auernhammer CJ; Spitzweg C; Boeck S; Unterrainer M; Gildehaus FJ; Böning G; Jurkschat K; Wängler C; Wängler B; Schirrmacher R; Bartenstein P
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):870-880. PubMed ID: 31492994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo evaluation of 64Cu-TETA-Tyr3-octreotate. A new somatostatin analog with improved target tissue uptake.
    Lewis JS; Srinivasan A; Schmidt MA; Anderson CJ
    Nucl Med Biol; 1999 Apr; 26(3):267-73. PubMed ID: 10363797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of [
    Njotu FN; Ketchemen JP; Tikum AF; Babeker H; Gray BD; Pak KY; Uppalapati M; Fonge H
    J Nucl Med; 2024 Apr; 65(4):533-539. PubMed ID: 38485273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.